SUN-VIIA (Fexo-Base) (CAS NO:83799-24-0)

SUN-VIIA (Fexo-Base) is a pharmaceutical intermediate used in the synthesis of Fexofenadine, a widely used antihistamine for treating allergic reactions, rhinitis, and chronic urticaria.

Primarily used in the pharmaceutical industry as a key API intermediate for antihistamine drug manufacturing.

Yes, it is subject to pharmaceutical regulatory compliance in different regions depending on its end use in API production.

SUN-VIIA is a critical API intermediate in the production of Fexofenadine HCl, ensuring consistent therapeutic efficacy and regulatory compliance in antihistamine drug manufacturing. It provides high yield and chemical purity, crucial for synthesis optimization in pharmaceutical R&D labs. This intermediate plays a key role in producing Fexofenadine-based allergy medications, known for their non-drowsy relief from allergies.

The high purity standards of SUN-VIIA minimize impurities in the final API, leading to enhanced product safety and reduced batch rejections. It ensures controlled reactivity and stereoselectivity, resulting in a highly pure and bioavailable antihistamine API. It enables safer and more effective allergy relief, providing fast-acting, non-sedative treatment.

Requires GMP manufacturing, COA (Certificate of Analysis), and compliance with ICH-Q7 and US FDA guidelines for pharmaceutical intermediates. Supports documentation for regulatory submissions and validation batches in drug development pipelines. Ensures the allergy medicines they take are safe, high-quality, and regulatory compliant.